Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BSenhwa Biosciences 〉CX-4945: CK2 Inhibitor Program

CX-4945: CK2 Inhibitor Program

CX-4945: CK2 Inhibitor Program

CX-4945, a synthetically derived small molecule, is provided as sodium salt in hard gelatin capsule shells with oral administration.

Request for Collaboration
Overview
CK2 (Casein kinase 2) is a protein kinase that has elevated activity in many cancers and has a direct role in DNA damage repair.  The DNA repair pathways enable tumor cells to survive damage induced by treatment with chemotherapeutic agents.  Inhibitors of DNA repair pathways have been shown to increase the efficacy of DNA-damaging chemotherapeutic drugs when these are used in combination.  Normal cells with DNA that do not replicate rapidly, as in fast growing cancer cells, and cells that have all of their DNA repair mechanisms intact are able to survive the temporary shutdown of one or more of these pathways.  Inhibiting CK2 has been shown to inhibit DNA repair, and this augments the lethality of the DNA damage in cancer cells that is caused by chemotherapy treatment.

CX-4945 is a selective, small molecule inhibitor of CK2.  It has demonstrated favorable safety, pharmacokinetic (PK) characteristics and pharmacodynamics (PD) responses in Phase I studies.  Clinical observations show that CX-4945 hits the CK2 target and modulates the expected pathways without displaying toxicity.  CX-4945 achieved clinical benefit as a single agent CK2 inhibitor, demonstrating stable disease and extended duration on treatment in a several patients.  A combination of CX-4945 with the DNA damaging agents such as gemcitabine (Gemzar) plus cisplatin (Platinol), has been shown to act synergistically to improve the efficacy of these anticancer treatments.  This combination is currently being developed for the treatment of advanced cholangiocarcinoma, a disease for which there are no currently effective therapies.

CX-4945 Mechanism



 
Application
Cholangiocarcinoma 
Basal Cell Carcinoma
Medulloblastoma
Pediatric Brain Tumor
Patent Portfolio
Senhwa's patent portfolio is comprised of 105 issued patents and 14 pending patent applications (by 19 May, 2017).  Intellectual property rights include patents covering product derivatives, pharmaceutical formulations, method of use, manufacturing process, crystalline forms and combination therapies.  Patents have been granted in the US, Europe, Canada, Japan, South Korea, China, Hong Kong, Russia, Australia, New Zealand and Taiwan.  Especially in the Europe, there are 19 countries have been registered to extent the market size for cancer therapy, including Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey, United Kingdom.
 
Collaboration Options

Licensing
Co-development
More Information
People who like this also like
  • TLC399TLC399
  • Carrier screening for fragile X syndromeCarrier screening for fragile X syndrome
  • Burixafor (TG-3000)Burixafor (TG-3000)
  • JHL1255 Ustekinumab BiosimilarJHL1255 Ustekinumab Biosimilar
  • Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)
  • R&D ManagementR&D Management
  • Lab FacilityLab Facility
  • TAT-HOXB4TAT-HOXB4
  • GLP LaboratoriesGLP Laboratories
  • Noninvasive prenatal screening by next generation sequencing of maternal plasma DNANoninvasive prenatal screening by next generation sequencing of maternal plasma DNA